These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 15041378

  • 1. Evolution of the therapeutic drug monitoring of cyclosporine.
    Citterio F.
    Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. C2 is an age-independent parameter for optimal cyclosporine exposure in long-term kidney transplant recipients.
    Ferraresso M, Citterio F, Ghio L, Romagnoli J, Edefonti A, Berardinelli L, Castagneto M.
    Transplant Proc; 2004 Nov; 36(9):2656-8. PubMed ID: 15621115
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
    Banner NR, David OJ, Leaver N, Davis J, Breen J, Johnston A, Yacoub MH.
    Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E, Delucchi MA, Cano F, Valdebenito S, Castillo MC, Villegas R.
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [Abstract] [Full Text] [Related]

  • 7. The impact of cyclosporine on the development of immunosuppressive therapy: perspective from a transplant nephrologist involved with the development of C2.
    Cole E, Deshpande R.
    Transplant Proc; 2004 Mar; 36(2 Suppl):408S-413S. PubMed ID: 15041376
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic drug monitoring of cyclosporine.
    Jorga A, Holt DW, Johnston A.
    Transplant Proc; 2004 Mar; 36(2 Suppl):396S-403S. PubMed ID: 15041374
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
    Oellerich M, Armstrong VW, Streit F, Weber L, Tönshoff B.
    Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
    [Abstract] [Full Text] [Related]

  • 11. [A new strategy for monitoring levels of cyclosporin A in the blood of patients after kidney transplantation].
    Halacová M, Jedlicková B, Průsa R.
    Ceska Slov Farm; 2003 Nov; 52(6):267-71. PubMed ID: 14661365
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacologic monitoring and outcomes of cyclosporine.
    Pollard SG.
    Transplant Proc; 2004 Mar; 36(2 Suppl):404S-407S. PubMed ID: 15041375
    [Abstract] [Full Text] [Related]

  • 14. Evidence of different pharmacokinetics between cyclosporine and tacrolimus in renal transplant recipients: why cyclosporine is monitored by C2 level and tacrolimus by trough level.
    Takeuchi H, Matsuno N, Hirano T, Toraishi T, Konno O, Nakamura Y, Iwamoto H, Hama K, Unezaki S, Nagao T.
    Transplant Proc; 2008 Sep; 40(7):2240-2. PubMed ID: 18790203
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A limited sampling strategy for the estimation of 12-hour cyclosporine neoral area under the curve in Chinese cardiac transplant recipients.
    Wang CH, Ko WJ, Chou NK, Wang SS.
    Transplant Proc; 2004 Oct; 36(8):2390-2. PubMed ID: 15561259
    [Abstract] [Full Text] [Related]

  • 18. [Efficacy of therapeutic monitoring of cyclosporine through C2 and AUC(0-4) during the first 24 months following kidney transplantation].
    Vavić N, Ignjatović L, Drasković B, Hrvacević R, Kovacević Z, Paunić Z.
    Vojnosanit Pregl; 2008 Feb; 65(2):119-27. PubMed ID: 18365668
    [Abstract] [Full Text] [Related]

  • 19. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
    John U, Ullrich S, Roskos M, Misselwitz J.
    Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
    [Abstract] [Full Text] [Related]

  • 20. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
    Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Hübler M, Abd El Rahman MY, Miera O, Ewert P, Weng Y, Wei H, Krüdewagen B, Hetzer R, Berger F.
    J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.